(Q33736270)

29 July 2017

1 reference

title

Extended-release dipyridamole/aspirin (English)

1 reference

29 July 2017

1 reference

Hervey PS

1

1 reference

29 July 2017

Goa KL

series ordinal

2

1 reference

29 July 2017

publication date

1 September 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

58

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

469-75; discussion 476-7

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199958030-00007

29 July 2017

exact match

0 references

cites work

The effect of combined aspirin and dipyridamole therapy on thrombus formation in an arterial thrombogenic lesion in the dog

1 reference

12 December 2020

The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group

1 reference

12 December 2020

Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo

1 reference

12 December 2020

Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia

1 reference

12 December 2020

Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group

1 reference

12 December 2020

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

12 December 2020

"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia

1 reference

12 December 2020

Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project.

1 reference

12 December 2020

European Stroke Prevention Study 2. Efficacy and safety data

1 reference

12 December 2020

European Stroke Prevention Study. ESPS Group

1 reference

12 December 2020

European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation?

1 reference

12 December 2020

Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis.

1 reference

12 December 2020

Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition

1 reference

12 December 2020

Effect of aspirin-dipyridamole and heparin and their combination on venous thrombosis in hypercoagulable or thrombotic animals

1 reference

12 December 2020

[Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial]

1 reference

12 December 2020

10.2165/00003495-199958030-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1027274440

0 references

1 reference